Synuclein-One Study (NCT04700722) | Clinical Trial Compass
CompletedNot Applicable
Synuclein-One Study
United States428 participantsStarted 2021-01-04
Plain-language summary
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Who can participate
Age range40 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female between 40-99 years of age
* Prior clinical diagnosis of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure
* Health Subjects, no history of clinical or symptoms suggestive with synucleinopathy
Exclusion Criteria:
* Clinical evidence of severe vascular disease (history of ulceration, poor wound healing, vascular claudication)
* Clinically active coronary artery or cerebrovascular disease
* Current smoker or alcoholism
* History of allergic reaction to local anesthesia for skin biopsies
* Use of blood thinners (aspirin or Plavix alone is allowed)
* Significantly impaired wound healing or history of scarring or keloid formation
* Healthy individuals or individuals with synucleinopathy is disease may be explained by other causes: recent history of encephalitis, Cortical dementia of Alzheimer's type, Whipple's disease, toxin exposure, repeated head injury and stepwise disease progression suggestive of vascular etiology